Cancer BiologybioRxivPreprint
Combined SHP2 and ERK inhibition for the treatment of KRAS-driven Pancreatic Ductal Adenocarcinoma
K. J. Ciecielski, A. Mulero-Sanchez, A. Berninger…·S. Mainardi
This paper investigates the combination of SHP2 and ERK inhibition as a treatment for KRAS-driven pancreatic ductal adenocarcinoma, showing synergistic anticancer effects and tumor regression in mouse models.
DOI 10.1101/2021.12.14.472574